The MCCC considers the Developmental Funds as one of the most critical components of CCSG support. Together with institutionally derived MCCC discretionary funds and the annual grant support from the Fraternal Order of Eagles, these funds have supported recruitment of new research faculty, shared resource development, and the initiation of research projects or generation of pilot data for subsequent peer review grant applications. Given the small size of the CCSG Developmental Fund pool relative to the substantial expansion realized over the last funding period, institutionally-derived MCCC discretionary funds and philanthropic sources have contributed more than 90% of the funding needed for pilot projects, program or shared resource initiation, and all funding for instrumentation and new laboratory set-up costs. Processes are firmly established in the MCCC to solicit and review proposals for CCSG Developmental Fund support. Funding is predicated on scientific merit, programmatic relevance, MCCC strategic priorities and, in the case of shared resource development, the unambiguous need of peer review investigators. An increase in Developmental Funds is requested in this application, though it is commensurate with the funding level recommended for the current funding period (but not awarded). These Developmental Funds will be leveraged with institutionally derived MCCC discretionary funds. Funding is requested in the next project period to support initiatives in the following categories: ? Continued recruitment of outstanding new research faculty - the MCCC is currently actively recruiting to fill 20 positions across its three campuses ? Pilot projects - to enable the MCCC to pursue outstanding science leading to peer review funding; including highly innovative but high-risk proposals that might otherwise not receive funding ? Development of shared resources - to insure the scientific vitality of MCCC investigators and programs The MCCC's Developmental Fund request represents approximately 8% of the direct costs requested. The MCCC has a proven track record in stewardship of these funds as evidenced by the 'return on investment'of new faculty recruited to the center during the current grant period. The current request, substantially buttressed by the continued commitment of MCCC discretionary funds, will enable the Director to support activities critical to the sustained research excellence of this Cancer Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-39
Application #
8465650
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-03-01
Budget End
2014-02-28
Support Year
39
Fiscal Year
2013
Total Cost
$330,609
Indirect Cost
$101,734
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Basch, Ethan; Rogak, Lauren J; Dueck, Amylou C (2016) Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials. Clin Ther 38:821-30
Renner, Danielle N; Malo, Courtney S; Jin, Fang et al. (2016) Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model. Neurotherapeutics 13:226-36
Navari, Rudolph M; Qin, Rui; Ruddy, Kathryn J et al. (2016) Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med 375:134-42
Amirian, E Susan; Zhou, Renke; Wrensch, Margaret R et al. (2016) Approaching a Scientific Consensus on the Association between Allergies and Glioma Risk: A Report from the Glioma International Case-Control Study. Cancer Epidemiol Biomarkers Prev 25:282-90
Cuellar-Partida, Gabriel; Lu, Yi; Dixon, Suzanne C et al. (2016) Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Hum Genet 135:741-56
Ye, Zi; Austin, Erin; Schaid, Daniel J et al. (2016) A multi-locus genetic risk score for abdominal aortic aneurysm. Atherosclerosis 246:274-9
McCormack, Valerie A; Burton, Anya; dos-Santos-Silva, Isabel et al. (2016) International Consortium on Mammographic Density: Methodology and population diversity captured across 22 countries. Cancer Epidemiol 40:141-51
Basal, E; Ayeni, T; Zhang, Q et al. (2016) Patterns of Müllerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian Cancer. Curr Mol Med 16:222-31
Vaidhyanathan, Shruthi; Wilken-Resman, Brynna; Ma, Daniel J et al. (2016) Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases. J Pharmacol Exp Ther 356:251-9
Yoon, H H; Foster, N R; Meyers, J P et al. (2016) Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance). Ann Oncol 27:339-44

Showing the most recent 10 out of 948 publications